+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Glucose Dependent Insulinotropic Receptor"

Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2020 - Product Thumbnail Image

Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 37 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The Glucose Dependent Insulinotropic Receptor (GIPR) is a receptor found in the endocrine and metabolic disorders drugs market. It is a G-protein coupled receptor that is activated by glucose and is involved in the secretion of insulin. GIPR agonists are used to treat type 2 diabetes, as they can increase insulin secretion and reduce blood glucose levels. GIPR antagonists are also being developed to treat obesity and other metabolic disorders. GIPR agonists are currently in clinical trials and have shown promising results in treating type 2 diabetes. GIPR antagonists are also being developed to treat obesity and other metabolic disorders. Companies in the GIPR market include Novo Nordisk, Eli Lilly, Merck, Sanofi, and AstraZeneca. Show Less Read more